Lyra Therapeutics, Inc. — Director's Dealing 2021

May 29, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyra Therapeutics, Inc. (LYRA)
CIK: 0001327273
Period of Report: 2021-05-26

Reporting Person: snyderman nancy lynn MD (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-26	Stock Option	$7.24	A	7250	Acquired	2031-05-25	Common Stock (7250)	Direct

Footnotes

F1: This option vests and becomes exercisable on the earlier of (i) May 26, 2022 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date.